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No-pharmacological Substance Group (n20,670). After risk adjustments, 10,376
patients from each group were matched. Patients in the No-Pharmacological Sub-
stance Group stayed longer in detoxification facilities, and had a higher number of
detoxification and/or rehabilitation admissions, which translated to a cost burden
of $2,654,000 per 1,000 patients. Also, patients in the No-Pharmacological Sub-
stance Group had more outpatient visits, and higher total healthcare costs during
the 6-month post-index period compared to patients in the Any Pharmacological
Substance Group. CONCLUSIONS: After controlling for confounders such as demo-
graphic factors, comorbid conditions and baseline healthcare utilization, we showed
that medication treatment affects the follow-up healthcare resource utilization and
costs. Pharmacological substance treatments were associated with lower healthcare
costs and utilizations than non-pharmacological substance treatments.
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OBJECTIVES: To compare expected clinical outcomes and economic costs in pa-
tients with chronic schizophrenia (including schizoaffective disorders) who are
treated with second-generation antipsychotics (SGAs).METHODS: Using a Markov
simulation model, we estimated expected clinical outcomes and economic costs
over one year in patients receiving SGAs (i.e., aripiprazole, asenapine, iloperidone,
olanzapine, quetiapine, risperidone, or ziprasidone) for treatment of schizophrenia
(including schizoaffective disorders). All SGAs were assumed to have equal effi-
cacy, and to differ only with respect to their side effects and costs. Side effects
considered included extrapyramidal symptoms (EPS), prolactin disorders, diabe-
tes, weight gain, metabolic syndrome, akathisia, sedation, somnolence, nausea/
vomiting, and QTc interval prolongation. Outcomes considered included the prob-
ability of therapy discontinuation due to side effects, and expected duration of
therapy. Costs included those of SGAs (only risperidone was assumed available
generically), treatment of side effects, and all psychiatric care (including relapse),
and were estimated from the perspective of the US healthcare system (2010 US
dollars). The periodicity of the model was one month. The model was run for a
hypothetical cohort of 25,000 patients. Patients were followed in the model until
therapy discontinuation, death, or one year, whichever occurred first. RESULTS:
Over one year, the number of patients estimated to discontinue therapy ranged
from 42% (ziprasidone) to 70% (olanzapine), and expected mean duration of ther-
apy ranged from 6.7 months (risperidone) to 8.6 months (ziprasidone). Total
monthly costs of psychiatric care ranged from $2718 (risperidone) to $3352 (olan-
zapine). Expected adherencewith treatmentwas higher, and, with the exception of
risperidone, which was generically available, costs of care were lower, for agents
with better tolerability.CONCLUSIONS:Tolerability is an important determinant of
adherence with SGAs and also total costs of psychiatric care.
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OBJECTIVES: To examine the relationship between average daily dose (ADD) of
duloxetine, medication adherence, and healthcare costs among patients with ma-
jor depressive disorder (MDD). METHODS: Using a large US administrative claims
database, commercially-insured patients aged 18-64 who initiated duloxetine in
2007 were identified. Initiation was defined as no duxolextine treatment over the
prior 90 days, with the corresponding duloxetine dispense date as the index date.
Patients were required to have 12-month continuous enrollment preceding and
following duloxetine initiation, and at least 1 MDD diagnosis during the 12months
prior to, or on the index date. Five cohorts were constructed based on ADD: 20-29,
30, 31-59, 60, and 60 mg/day. Healthcare costs and duloxetine adherence (mea-
sured via medication possession ratio), were assessed over the 12-month post-
index period. Multivariate regression models adjusting for differences in demo-
graphic and clinical characteristics were used to examine the association between
ADD, adherence and healthcare costs. RESULTS: The study sample included 8572
MDD patients with 60.7% initiating duloxetine at 60 mg/day. During the 12-month
post-index period, 3.4% of patients had an ADD of 20-29, 9.0% of 30, 21.3% of 31-59,
37.2% of 60, and 29.1% of 60 mg/day. Controlling for demographics and clinical
characteristics, patients in the 31-59 or 60 mg/day cohorts (30 mg/day) were
more (less) likely to adhere to duloxetine than those with 60 mg/day (all p0.05).
Comparedwith patientswith anADDof 60mg/day, thosewith anADD60mg/day
had significantly higher total healthcare costs ($3,947, p0.05), while those with an
ADD of 30 mg/day had significantly lower costs (-$1,109, p0.05). CONCLUSIONS:
The findings suggest that having an ADD of 60 mg/day for duloxetine among com-
mercially insured MDD patients is associated with improved medication adher-
ence relative to low duloxetine doses and lower healthcare costs relative to high
duloxetine doses.
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OBJECTIVES: To identify patients with treatment-resistant depression (TRD) using
the Massachusetts General Hospital (MGH) claims signature and examine health-
care costs.METHODS: This retrospective study identified patients 18-64 years with
an antidepressant medication claim (index date) and at least two ICD-9-CM codes
for depression. Patients were excluded if they had any other psychiatric disorder.
Each patient was assigned anMGH score, a validatedmeasure of depressive sever-
ity, based on points associated with utilization of electroconvulsive therapy (ECT),
antidepressants and adjunctive therapies (atypical antipsychotic, mood stabilizer,
stimulant) within two years following index date. An MGH score of  3.5 signified
TRD. For patients with an additional year of pharmacy andmedical coverage (i.e., 3
years following index date), direct medical costs (hospitalizations, office visits,
emergency department visits and prescription medications) were calculated.
RESULTS:The cohort consisted of 20,089 patientswith amean [SD] age of 42.7 [11.3]
years and 72.6% women. Only 0.09% of patients had an ECT claim while 28.6% of
patients had at least one prescription claim for an adjunctive therapy (24.0% for
atypical antipsychotics, 13.3% for mood stabilizers and 14.6% for stimulants). TRD
(i.e., MGH score  3.5) was identified in 31.2% of patients. Cost data was available
for 18,720 patients and showed a mean 16.5% increase in cost for each 1 point
increase in MGH score. Patients with TRD had a mean $2,274 higher annual direct
medical costs, a 45% increase in costs, compared with non-TRD patients (i.e., MGH
score 3.5). CONCLUSIONS: Using a claims signature, we found a high prevalence
and cost of TRD in a commercialmanaged care organization. Identifying patients is
an important step in addressing the burden of TRD. Future research should deter-
mine effective interventions which improve clinical remission rates in this patient
population.
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OBJECTIVES: This study examined real-world estimates of healthcare utilization
and costs of newly diagnosed depressed patients following their initial depression
diagnosis compared to an age- and gender-matched cohort without depression.
METHODS:A cohort of patientswith a depression diagnosis (ICD-9-CM 296.2, 296.3,
298.0, 300.4, 309.0, 309.1, 309.28, or 311) in 2006 and an age- and gender-matched
comparator cohort were extracted from the Thomson Reuters MarketScan® data-
base. The index date for each patient was the date of initial depression diagnosis.
Comparator patients were randomly assigned an index date. Study subjects were
required to be free of depression with no evidence of antidepressant use for 1 year
prior to their index date. The study period began at the index date and continued
until either the last day of the study period, December 31, 2008, or earlier if the
patient was lost to follow-up. Medical care utilization and costs were assessed for
the depressed and comparator cohorts. RESULTS: A total of 175,092 patients with
diagnosed depression were included in the analysis. Total utilization (sum of visits
plus prescriptions) was approximately 2.1-fold greater among depressed patients
than among the comparator cohort (34.3 vs. 16.2 per patient-year), a difference
driven by outpatient visits (17.56 vs. 6.58 per patient-year). Total health care costs
for the depressed cohort were more than 2.7-fold greater than for the comparator
cohort ($10,840 vs. $3,980 per patient-year). Results were consistent throughout
virtually all major utilization and prescription dispensing categories and generally
increased with increasing age. Follow-up utilization and costs for comparators
were similar to baseline (15.6 and $3,420 at baseline), whereas these metrics in-
creased 40% and 58% (24.5 and $6,840 at baseline) for depressed patients following
their depression diagnosis. CONCLUSIONS: Compared to age- and gender-
matched depression-free comparators, depressed patients had substantially
higher health care utilization and costs.
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OBJECTIVES: The aim of the study was to estimate the direct costs associated with
schizophrenia in the non-institutionalized U.S. population. METHODS: Patients
with a diagnosis of ‘schizophrenia and other psychoses’ (clinical classification code
659) between January 1, 2005 and December 31, 2008 were identified from the
Medical Expenditure Panel Survey (MEPS) database. The costs for the following
categories were identified: inpatient hospitalizations (IHs), outpatient visits (OVs),
emergency department visits (EDs), physician office visits (MDVs), home health-
care visits (HHCVs), and prescription medication costs (RX). The ‘surveymeans’
procedure of SAS was used for statistical analyses as it accounts for the complex
sampling design used by MEPS. RESULTS: A total of 1,519,019 patients with schizo-
phrenia were identified. Themean age (SE) was 41.8 years (1.5) and 68.5% of the
populationwasmale. Themajority (77.2%) had public insurance, 15.3% had private
insurance, and 7.5% were uninsured. There were 300,176 IHs, 347,621 OVs,
1,439,416 MDVs, 276,369 EDs, 175,813 HHCVs, and 1,437,476 RX purchases associ-
atedwith schizophrenia. The total cost estimates for each categorywere as follows:
$4.7 billion (27.1%) for IHs, $847.7 million (4.9%) for OVs, $3.4 billion (19.8%) for
MDVs, $224.1 million (1.3%) for EDs, $1.8 billion (10.3%) for HHCVs, and $6.3 billion
(36.6%) for RX purchases. The total direct costs and the average annual costs were
$17.3 billion and $4.32 billion, respectively. CONCLUSIONS: Our estimate of $17.3
billion is different fromestimates in previous studies due to differences in selection
of patients and cost categories included. The high costs associated with prescrip-
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